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AbstrAct
Metastasis is a multistep molecular network process, which is lethal for more than 
90% of the cancer patients. Understanding the regulatory functions of metastasis-
inducing molecules is in high demand for improved therapeutic cancer approaches. 
Thus, we studied the post-transcriptional regulation of the crucial carcinogenic and 
metastasis-mediating molecule metastasis associated in colon cancer 1 (MACC1). 
In silico analysis revealed MACC1 as a potential target of miR-218, a tumor suppressor 
miRNA. Expression of these two molecules inversely correlated in colorectal cancer 
(CRC) cell lines. In a cohort of CRC patient tissues (n = 59), miR-218 is significantly 
downregulated and MACC1 is upregulated compared with normal mucosa. Luciferase 
reporter assays with a construct of the MACC1-3ʹ-UTR harboring either the wild type 
or the mutated miR-218 seed sequence confirmed the specificity of the targeting. 
miR-218 inhibited significantly MACC1 protein expression, and consistently, MACC1-
mediated migration, invasion and colony formation in CRC cells. Anti-miR-218 
enhanced the MACC1-mediated migration, invasion and colony formation. Similar 
findings were observed in the gastric cancer cell line MKN-45. Further, we performed 
methylation-specific PCR of the SLIT2 and SLIT3 promoter, where miR-218 is encoded 
in intronic regions. The SLIT2 and SLIT3 promoters are hypermethylated in CRC 
cell lines. miR-218 and SLIT2 expressions correlated positively. Methyltransferase 
inhibitor 5-Azacytidine induced miR-218 expression and inhibited the expression of 
its target MACC1. We also determined that MACC1 has alternative polyadenylation 
(APA) sites, which results in different lengths of 3ʹ-UTR variants in a CRC cell line. 
Taken together, miR-218 is post-transcriptionally inhibiting the MACC1 expression 
and its metastasis-inducing abilities.
INtrODUctION
Metastasis associated in colon cancer 1 (MACC1) 
was identified through differential display RT-PCR analysis 
of normal colon mucosa, colorectal cancer (CRC) and 
respective metastasis tissue specimens in our group [1]. 
MACC1 induces the crucial step of carcinogenesis transition 
from adenoma to carcinoma in mice and human [2, 3]. In 
CRC and its prime metastasized organs liver and lung, 
MACC1 was found to be significantly upregulated when 
compared to mucosa and adenoma [1, 4–7]. The five year 
metastasis-free survival (MFS) of CRC patients with low 
MACC1 expression was 80%, whereas the five year MFS 
rate dropped down to 15% for CRC patients with high 
MACC1 expression. Thus, high expression of MACC1 
in tumor specimens served as an independent prognostic 
marker for MFS [1,8]. Since its discovery, numerous studies 
in a variety of different solid cancer entities such as CRC, 
gastric and hepatocellular carcinoma, demonstrated that 
MACC1 serves as a prognostic biomarker for patient tumor 
progression and metastasis [5, 6, 9–12]. 
High expression of MACC1 induced proliferation, 
migration and invasion of cancer cell lines and induced 
tumor growth and metastasis formation in mice [1, 13]. 
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First, MACC1 was identified as transcriptional regulator 
of the proto-oncogene c-Met [1]. In the meantime, gain 
or loss of function experiments revealed additional 
molecules and signaling axis like Akt, E-Cadherin, 
c-Myc, GSK3β and caspase 3 to be regulated by MACC1 
[14–18]. Therefore, MACC1 is one of the key regulators 
of hallmarks of cancer like cell proliferation, apoptosis, 
metastatic events (migration, invasion, epithelial 
mesenchymal translation (EMT)) and angiogenesis, as 
well as its role in cancer cell metabolism [1, 17–21]. 
microRNAs (miRs) are single-stranded RNAs of 19 
to 25 nt length, which mostly bind to the 3ʹ untranslated 
regions (UTR) of classical protein coding genes and 
inhibit the target gene expression either by degrading the 
respective mRNA or by inhibiting its translation [22]. 
miRs are also transcriptionally regulated, for example 
by epigenetic modifications [23, 24]. Loss of regulation 
control at the transcriptional and post-transcriptional levels 
of MACC1 lead to its overexpression in numerous cancer 
entities, which causes cancer progression [11, 25–27]. 
miR-218 is a tumor suppressor miR, which is 
downregulated in different cancer entities [28]. The mature 
miR-218 is encoded in two precursor subtypes miR-
218_1 and miR-218_2, which both are located in introns 
of SLIT2 and SLIT3, respectively. The expression status 
of miR-218 depends on the promoter activity of its host 
genes [29, 30]. From the literature and gene expression 
depository databases, like The Cancer Genome Atlas 
(TCGA) and Gene Expression Omnibus (GEO), we know 
that miR-218 is downregulated and, simultaneously, 
MACC1 is upregulated in different cancer entities [11, 
28]. In silico predictions revealed that the MACC1-3ʹ-
UTR contains several predicted binding sites for the 
miR-218-5p specific target sequence to which it can 
bind via its specific seed sequence. These findings and 
the importance of these molecules in cancer disease 
motivated us to explore the role of miR-218 in the post-
transcriptional regulation of MACC1. As a result of our 
study, we identified that MACC1 and miR-218 expression 
levels correlated inversely in a panel of CRC cell lines. 
Further, expression levels of MACC1 and miR-218 were 
significantly upregulated or downregulated in a cohort of 
CRC patient specimens, respectively. The miR-218 host 
genes SLIT2 and SLIT3 are hypermethylated in a panel of 
CRC cell lines. Overexpression of miR-218 significantly 
downregulated the MACC1 expression and inhibited 
the MACC1-induced colony formation, migration and 
invasion in both CRC and gastric cancer cell lines. In 
addition, we revealed that MACC1 possesses alternative 
polyadenylation (APA) sites. Taken together, these data 
demonstrate that miR-218 is inhibiting, at least in part, the 
MACC1-mediated tumor progressive events.  
rEsULts 
mir-218 expression correlated inversely with 
MAcc1 expression in crc cell lines 
To investigate an in vitro relevance of the miR-218- 
and MACC1-expression in CRC cell lines, the expressions 
of these two molecules were measured at the transcript 
level. A significant inverse correlation between these two 
genes (ρ = –0.818, P = 0.002) was found in CRC cell lines. 
MACC1 mRNA and its protein amount, however, were not 
significantly correlated. For example, among the screened 
CRC cell lines, SW620 cells had the highest MACC1 
protein amount and 31-fold higher mRNA expression 
compared to SW480 cells. Whereas, Caco-2 and DLD-
1 cells had moderate endogenous protein amounts when 
compared with SW620 cells, but the relative MACC1 
mRNA expression in Caco-2 and DLD-1 cells was higher 
than in SW620 cells (Figure 1A). This result shows that 
MACC1 mRNA expression levels not always correlate 
with protein expression in the analyzed CRC cell line 
panel. 
To have further insights of the potential inverse 
miR-218- and MACC1-expression correlation in the 
clinical situation, we screened a cohort of CRC patient 
tumor specimens and representative normal mucosa 
samples. Although no significant inverse correlation 
was found, miR-218 was significantly downregulated 
and MACC1 significantly upregulated in tumor tissues 
compared to the normal mucosa (Figure 1B). Apart from 
this significant regulation, we did not find any other 
significant correlation of clinicopathological factors with 
miR-218 expression. These in vitro and in vivo expression 
studies of these two genes miR-218 and MACC1 
prompted us to investigate the post-transcriptional 
regulation of MACC1 by miR-218. 
The MACC1-3ʹ-UTR is a target for miR-218
The 6299 nt long 3ʹ-UTR of MACC1 
(#NM_182762) was screened for complementary seed 
sequences of known miRNAs via in silico prediction 
tools (TargetScan, RNAHybrid). A high threshold 
seed sequence for miR-218 at nt 218-224 was found 
(Figure 2A). Given the results from the expression and 
in silico analyses, we asked whether the 3ʹ-UTR of 
MACC1 is a functional target of miR-218. To address this 
question, we cloned 6016 nt of the 3ʹ-UTR of MACC1, 
harboring the miR-218 seed sequence, in pmirGLO 
dual luciferase vector at the 3ʹ-position of a luciferase 
reporter gene (MACC1-3ʹ-UTR). The MACC1-3ʹ-UTR 
was co-transfected along with miR-218 into HCT116, 
SW620 and SW480 cells. The luciferase activity of 
miR-218-transfected MACC1-3ʹ-UTR was significantly 
reduced when compared with control-miR (Figure 2B). 
Similarly, a co-transfection with the mutated miR-218 
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seed sequence construct did not show any significant 
reduction in luciferase activity (in HCT116, SW620) 
when compared with its control-miR. However, reduced 
luciferase activity was determined for both wild type and 
mutated MACC1-3ʹ-UTR co-transfected with miR-218 in 
SW480, which could be due to additional miR-218 seed 
sequences within the 6.0 kb of MACC1-3ʹ-UTR or miR-
218-mediated secondary effects. Taken together, these 
data suggest that the 3ʹ-UTR of MACC1 is a functional 
target for miR-218. 
miR-218 regulates the MACC1 gene expression 
In order to corroborate the results of the reporter 
assay, HCT116, SW620 and SW480 cells were 
transfected with control-miR, miR-218 or anti-miR-218 
(complementary sequence to mature miR-218, which 
inhibits the function of miR-218 by complementary 
binding). The transfection efficiency of the miR-218 
expression was measured by qRT-PCR (Figure 3A). 
Expression analyses showed that miR-218 reduced 
Figure 1: miR-218 and MACC1 expression is inversely correlated in CRC cell lines and are significantly down or 
upregulated in CRC tumor specimens, respectively. (A) Relative miR-218 and MACC1 expressions in a panel of CRC cell 
lines were analyzed by qRT-PCR, whereas RNUB6 and RPII served as internal controls. miR-218 and MACC1 expressions are inversely 
correlated (ρ = –0.818, P = 0.002 ). Protein amounts of MACC1 were screened in the same panel of CRC cell lines. β-actin served as 
internal control. (b) miR-218 and MACC1 expression was measured using tumor tissue of 59 CRC patients normalized to representative 
normal specimens. miR-218 was significantly downregulated (P = 0.016) and MACC1 was significantly upregulated (P < 0.001) in CRC 
tissues. RNUB6 and RPII served as internal controls.
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MACC1-transcript levels, but no changes were observed in 
anti-miR-218 condition, when compared with the control-
miR. Western blotting confirmed the downregulation of 
MACC1 protein amounts in cells transfected with miR-218. 
On the other hand, an upregulation of the MACC1 protein 
amount was observed in cells transfected with anti-miR-218 
in comparison to the control-miR (Figure 3B, 3C). Taken 
together, these results suggest that miR-218 is regulating 
MACC1 at the transcript level and most significantly by 
translation inhibition via binding to its 3ʹ-UTR.
miR-218 inhibits MACC1-induced colony 
formation, migration and invasion 
To further investigate the functional ability of 
miR-218 in mediating cancer metastatic events we have 
performed colony formation, migration and invasion 
assays by transfecting SW480 cells with either a control-
miR, miR-218 or anti-miR-218 inhibitor. Colony 
formation assay was performed with soft agar, migration 
(without matrigel) and invasion (with matrigel) assays 
were performed with Boyden chamber transwells. Ectopic 
overexpression of miR-218 significantly reduced the 
colony formation, migrating and invading capacity of 
SW480 cells when compared with control-miR expressing 
cells (Figure 4A–4C). Ectopic overexpression of miR 
inhibitor anti-miR-218 significantly induced migration 
(Figure 4A). The cells also showed an induced invasion 
and colony formation when compared with the control-
miR expressing cells (Figure 4B, 4C). In addition, we also 
investigated the effect of miR-218 on cell viability, but 
there was only a minor effect on proliferation detectable 
in SW480 cells (Supplementary Figure S1A).
Rescue experiments were performed with 
MACC1 stably expressing SW480 cell line with ectopic 
overexpression either of miR-218 or the respective 
control-miR along with the SW480-empty vector (e.v.) 
control cell line. Transfection efficiency of miR-218 
expression and MACC1 expression was measured 
with qRT-PCR and Western blot analysis, respectively 
(Figure 4D–4F). In parallel to previous results with 
SW480 cells, in this setup the SW480-empty vector 
control cells showed similar results of migration, 
invasion and colony formation after miR-218 ectopic 
overexpression. As expected, the SW480-MACC1 cell 
line induced migration and invasion when compared to 
SW480-empty vector cell line (Figure 4G, 4H). miR-218 
ectopic overexpression resulted in reduced migration 
and invasion in SW480-empty vector cells, but did not 
show any significant inhibition of migration and invasion 
in SW480-MACC1 cells, when compared with its 
miR-control transfected cells (Figure 4G, 4H). Similar 
functional effect was observed with colony formation 
assay (Figure 4I). Additionally, we observed increased 
ectopic MACC1 expression in miR-218 co-transfected 
cells comparative to miR-control cells. This could be due 
to the global effect of miR-218, which might be driving 
the CMV promoter or stabilizing the mRNA binding 
proteins. However, other possible molecular mechanisms 
cannot be ruled out.  
Figure 2: miR-218 targets the MACC1-3ʹ-UTR. (A) Secondary structure prediction (RNAhybrid) of the binding between the seed 
sequence within the MACC1-3ʹ-UTR (position 218 to 224 nt) and miR-218 (green-highlighted sequence) revealed a hybridization energy 
∆G of –16.3 kcal/mol. Representation of MACC1-3ʹ-UTR with miR-218 binding region and schematic presentation of mutated region 
of miR-218 seed sequence (red-labled bases were mutated). (b) Luciferase reporter assays of MACC1-3ʹ-UTR wild type and mutated 
construct in HCT116, SW620 and SW480. Both wild type and mutated MACC1-3ʹ-UTR are co-tranfected either with control-miR (ctrl) or 
miR-218. Percent luciferase activity was calculated with the respective control (*P < 0.05; **P < 0.01). 
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Taken together, these results indicate that miR-
218 significantly inhibits different steps of MACC1-
mediated metastasis including migration, invasion and 
colony formation. miR-218 induced changes can be in 
part rescued by MACC1 overexpression which indicates 
MACC1 as novel target and mediator of the tumor 
suppressor miR-218 function. 
mir-218 inhibited the MAcc1 expression and 
its mediated tumor progressive effects in gastric 
cancer 
To determine in general the functional role of miR-
218 for the post-transcriptional regulation of MACC1, we 
have used an additional cancer entity of the gastrointestinal 
tract, employing the gastric cancer cell line MKN-45. 
Consistent with our results performed with CRC cell lines, 
MACC1 is also a target of miR-218 in gastric cancer cells. 
Luciferase assay, qRT-PCR and Western blot analyses 
performed with MKN-45 cells revealed that MACC1 
is post-transcriptionally regulated by miR-218 (Figure 
5A–5C). In addition, miR-218 reduced the cell viability 
of MKN-45 cells (Supplementary Figure S1B). We have 
performed functional experiments with control-miR, miR-
218, si MACC1 and both miR-218 and si MACC1. Ectopic 
overexpression of miR-218 or si MACC1 significantly 
reduced the migration, invasion and colony formation 
in comparison to the respective experimental controls. 
Figure 3: miR-218 downregulates MACC1 expression. (A) Expression of miR-218 in the transfected conditions was quantified 
using qRT-PCR. RNUB6 was used as internal control. (b) MACC1 mRNA and protein expression after transfection of control-miR, 
miR-218 and anti-miR-218 was determined using qRT-pCR and Western blotting. RPII was used as internal control for MACC1 mRNA 
expression and β-actin for Western blotting. Either miR-218 or anti-miR-218 did not regulate the MACC1 mRNA expression significantly, 
but mainly regulated the MACC1 at protein level, in these three cell lines. (c) Densitometric analysis of MACC1 protein bands normalized 
to β-actin represented as a mean value of triplicates, in comparison to the respective control. (*P < 0.05; **P < 0.01).
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A combination of both miR-218 and si MACC1 further 
reduced migration, invasion and colony formation when 
compared with the individual respective control conditions. 
Ectopic overexpression of miR-218 and knock-down of 
MACC1 showed the most significant reduction when 
compared with experimental controls (Figure 5D–5F). This 
could be due to the lack of MACC1 expression as one of the 
important post-transcriptional targets of miR-218, indeed 
miR-218 could actively inhibit other targets. However, one 
cannot exclude other biological functions mediated due to 
this condition. These cumulative evidences suggest that 
miR-218-induced effects on migration, invasion and colony 
formation in different cancer entities are at least in part a 
result of the inhibition of the MACC1 expression.
Figure 4: miR-218 inhibits the MACC1 mediated tumor metastasis events of CRC. (A, b) SW480 cells were transfected with 
miR-218 or anti-miR-218. After 48 h cells were plated on top of the Boyden chambers for migration and matrigel-coated Boyden chambers 
for invasion. After 15 h the migrated or invaded cells were measured as described in the materials and methods. (c) After 48 h of respective 
control-miR (ctrl), miR-218 and anti-miR-218 (anti-218) transfection, cells were seeded in agar plates and counted as described in material 
and methods. Numbers of colonies are represented in relation with the control condition as percentage. (D) Relative expression of miR-
218 after transfection in SW480-empty vector (e.v.) control cells and SW480-MACC1 stably expressing cells. (E, F) MACC1 mRNA 
and protein expression after miR-218 transfection were quantified using qRT-PCR and Western blotting. (G–I) Migration, invasion and 
colony formation assays of SW480-e.v and SW480-MACC1 either with control-miR or miR-218. Data are represented as the percentage 
of migrating or invading cells and colonies as mean ± SEM of their biological replicates, each experiment performed in three technical 
replicates. Densitometric analysis of MACC1 protein bands normalized to β-actin represented as a mean value of triplicates, in comparison 
to the respective control. (*P < 0.05, **P < 0.01, ***P < 0.001)
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miR-218 is downregulated in CRC cell lines due 
to a promoter hypermethylation of its host genes 
sLIt2 and sLIt3
As determined earlier in this study, miR-218 is 
downregulated in CRC cell lines and tumor specimens in 
comparison to normal tissue samples. Moreover, miR-218 
is reported to be downregulated across different cancer 
entities like for example glioblastoma, nasopharyngeal 
and non-small cell lung cancer [28, 29, 31–33]. It is also 
known that miR-218 can be epigenetically silenced e.g. 
by promoter hypermethylation which induces esophageal 
carcinogenesis [34]. These reports prompted us to study 
the mechanisms behind the downregulation of miR-218 
in CRC. With this regard, we analyzed the expression 
of the miR-218 and its host gene SLIT2 by qRT-PCR in 
our panel of CRC cell lines and found that the miR-218 
expression correlated positively with the SLIT2 expression 
(Figure 6A). For better representation of SLIT2 and miR-
218 expression, log
10 
transformed expression values were 
shown as Supplementary Figure S2 (R2 = 0.95; P < 0.001).
This made us to check methylation status of the 
SLIT2 and SLIT3 promoters with the published primer set 
by Narayan [30]. For this, DNA was isolated from a panel 
of CRC cell lines and subjected to bisulfite conversion and 
to a subsequent methylation-specific PCR. Here, primer 
pairs specific for the methylated or unmethylated CpG 
island promoter region of SLIT2 and SLIT3 were used 
(Figure 6B). The SLIT3 promoter was hypermethylated 
in all the eleven screened CRC cell lines. Moreover, the 
Figure 5: miR-218 inhibits the MACC1 mediated tumor metastasis events of MKN-45, a gastric cancer cell line. (A) 
Both wild type and mutated MACC1-3ʹ-UTR were co-transfected either with control-miR (ctrl) or miR-218 and luciferase activity were 
quantified. Percent luciferase activity was calculated with the respective control. (b) Relative expression of miR-218 after transfection in 
MKN-45 transfected control (ctrl), miR-218, si MACC1 and both miR-218 and si MACC1. (c) MACC1 mRNA and protein amounts after 
miR-218 and si MACC1 transfection were quantified using qRT-PCR and Western blotting. RPII was used as internal control. β-actin was 
used as internal control for Western blotting. (D–F) Migration, invasion and colony formation assays of MKN-45 either with control-miR 
(ctrl), miR-218, si MACC1 or in combination of miR-218 and si MACC1. Data are represented as the percentage of migrating or invading 
cells and colonies as mean ± SEM of their biological replicates, each experiment with three technical replicates. Densitometric analysis of 
MACC1 protein bands normalized to β-actin represented as a mean value of triplicates, in comparison to the respective control. (*P < 0.05, 
**P < 0.01, ***P < 0.001)  
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SLIT2 promoter was mostly methylated, like for example 
in CaCo-2 cells, which showed consequently also a 
relative low miR-218 expression (Figure 6B). However, 
there were also cell lines with a more unmethylated 
SLIT2 promoter like Colo206f or Colo320DM, which 
showed the highest miR-218 expression in the qRT-PCR 
comparatively (Figure 6B, Figure 1A). To sum up, the 
hypermethylation of the two host genes SLIT2 and SLIT3 
could be the reason for the miR-218 downregulation in 
most of the screened cell lines.
miR-218, known to inhibit tumor metastasis 
formation was also significantly downregulated in CRC 
patient specimens [28, 29]. In this front, we wanted 
to investigate the clinical relevance of the SLIT2 and 
SLIT3 promoter methylation in metachronous metastasis 
positive and negative tumor specimens of CRC patients. 
Surprisingly, we haven’t found any significant change in 
the methylation pattern of miR-218 host genes or in its 
expression between these two groups (Figure 6C, 6D). 
This could mean that a miR-218 downregulation might be 
an early event in primary tumor progression independent 
of metastasis formation.
5-Aza treatment reactivates miR-218 expression 
and inhibits MAcc1 expression 
In order to further differentiate the epigenetic 
regulation mechanism of miR-218 and MACC1, the two 
CRC cell lines SW480 and SW620 were treated with a 
selective inhibitor of DNA methyltransferases 5-aza-2ʹ-
deoxycytidine (5-Aza). Cells were treated for 72 h with 
2 μM 5-Aza by changing the medium with the drug or the 
DMSO control every 24 h, respectively. Interesting results 
were observed regarding the MACC1-3ʹ-UTR luciferase 
activity and the MACC1 gene expression after 5-Aza 
treatment. Both of the cell lines showed an induction 
of miR-218 and SLIT2 expression (Figure 7A, 7B). 
Consistently, significantly reduced luciferase activities 
were observed after 5-Aza treatment (Figure 7C). These 
observations resulted in significant downregulation 
of MACC1 in both cell lines at the mRNA and protein 
level (Figure 7D). This could be due to global effects 
of 5-Aza on the promoter methylation status of other 
miRs or transcriptional regulators that might affect the 
MACC1 expression. These data suggest that the epigenetic 
downregulation of miR-218 leads to an upregulation of 
MACC1 at least in part due to the loss of the miR-218 
function in CRC cell lines and tumor specimens. 
MAcc1 possesses alternative polyadenylation 
(APA) sites
Recent technical advancement of sequencing 
methods revealed that protein coding gene transcripts 
possess alternative polyadenylation (APA), and have 
shorter 3ʹ-UTR both in cancer cells and in cancer 
specimens when compared with healthy controls [35–37]. 
A full length 3ʹ-UTR of a specific gene is unavoidable 
Figure 6: Methylation status of miR-218 host genes SLIT2 and SLIT3 promoters in CRC cells and CRC metachronous 
metastasis positive and negative specimens. (A) miR-218 and SLIT2 expression were measured using qRT-PCR and positively 
correlated in a panel of CRC cell lines (R2 = 0.95). (b) Gel electrophoresis of PCR products of CRC cell lines obtained from methylation-
specific PCR for miR-218_1 hosting gene SLIT2 and miR-218_2 hosting gene SLIT3. (c) miR-218 expression in metachronous metastasis 
positive and negative CRC tumor specimens in comparison to representative normal mucosa. RPII and RNUB6 served as internal controls. 
(D) Gel electrophoresis of PCR products of CRC tumor specimens obtained from methylation-specific PCR for miR-218_1 hosting gene 
SLIT2 and miR-218_2 hosting gene SLIT3. 
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for a comprehensive post-transcriptional regulation 
by miRNAs. Further, it is also known that some of the 
important cancer-related genes have shorter 3ʹ-UTRs 
in cancer tissue than in normal tissues due to APA sites 
[35, 38]. Due to this reason and the important role of 
MACC1 upregulation in different cancer entities, we have 
investigated whether MACC1-3ʹ-UTR contains any APA 
sites (Figure 8A). 
We performed 3ʹ-RACE experiment using 
the CRC tumor cell line SW620 and found that 
MACC1 possesses several APA sites in these cells 
(Figure 8B). SW620 cells have the highest MACC1 
protein expression and transcribe the longest 3ʹ-UTR 
which harbors miR-218 seed sequences. Therefore, 
this regulatory mechanism does not affect the post-
transcriptional regulation of MACC1 by miR-218 in 
this cell line. However, in dealing with MACC1 APA 
sites a broader screening is required between different 
cancer cell lines and entities for better understanding of 
this phenomenon.
Figure 7: 5-Aza treatment induced miR-218 expression and downregulated MACC1 gene expression. SW480 and SW620 
cells were treated with 5-Aza (2 μM) for 3 days and total RNA and protein were isolated. (A, b) qRT-PCR revealed induction of miR-218 
and its host gene SLIT2 expression. (c) Luciferase activity of MACC1-3ʹ-UTR was significantly reduced after 5-Aza (2 μM). (D) qRT- 
PCR and Western blot analysis revealed inhibition of MACC1 expression in the 5-Aza treated samples compared to DMSO treated controls. 
RNUB6, RPII and β-actin served as internal controls. Densitometric analysis of MACC1 protein bands normalized to β-actin represented 
as a mean value of triplicates, in comparison to the respective control. 
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DIscUssION
In this study, we report that the tumor suppressor 
miR-218 post-transcriptionally downregulates MACC1. 
Expression of miR-218 is inversely correlated with the 
expression of MACC1 in a panel of CRC cell lines. 
miR-218 and MACC1 expression were significantly 
down- or upregulated respectively in a cohort of CRC 
tumor specimens. In vitro ectopic overexpression of 
miR-218 significantly inhibited the luciferase activity 
of MACC1-3ʹ-UTR and MACC1 protein expression, as 
well as MACC1-induced migration, invasion and colony 
formation in CRC and gastric cancer cells. miR-218 
and its host gene SLIT2 expression levels are positively 
correlated but there was no significant differences in 
miR-218 expression between metachronous metastasis 
positive and negative CRC tumor specimens. Secondly, 
miR-218 host genes SLIT2 and SLIT3 promoters are 
hypermethylated in the majority of CRC cell lines and 
tumor specimens. 5-Aza treatment significantly induced 
the expression of SLIT2 and miR-218 expression and 
inhibited the MACC1-3ʹ-UTR luciferase activity and 
MACC1 expression. We also determined that MACC1 
possesses alternative polyadenylation sites, which 
determines the availability of the 3ʹ-UTR for the post-
transcriptional regulation by miRs. 
miR-218 is an intronic miR of SLIT2 and SLIT3, 
which are epigenetically silenced in different cancer cells 
and tissues [30, 34, 39]. In parallel, a downregulation of 
miR-218 was also reported in various cancers entities 
like esophageal, hepatocellular, pancreatic, gallbladder, 
osteosarcoma, nasopharayngeal, colorectal, non-small 
cell lung cancer and breast cancer, which could be due 
to the epigenetic silencing of its host gene in the tumor 
cells [28, 29, 31, 34, 40–45]. Patients diagnosed with 
malignant glioma, gastric or colorectal cancer showing 
a low miR-218 expression had a shorter disease-free 
survival [31, 46, 47]. On the other hand, high MACC1 
expression was shown to be prognostic for shorter survival 
in several entities [8, 11, 48, 49]. In this present study, 
we also found miR-218 and MACC1 gene expression was 
significantly down- or upregulated, respectively, in CRC 
tumor specimens. In support of this inverse regulation of 
these two genes, luciferase reporter assay, qRT-PCR and 
Western blot analysis confirmed the post-transcriptional 
regulation of MACC1 by miR-218 in both CRC and 
gastric cancer cell lines. 
miR-218 is a post-transcriptional regulator of the 
receptor Roundabout1 (Robo1) and acts via inhibiting 
the SLIT-Robo1-mediated tumor migration, invasion in 
different cancer entities [29, 47]. The epigenetic silencing 
of miR-218 leads to Robo1 overexpression and activation 
of the signaling axis after its interaction with SLIT2 
[29, 50]. Along with Robo1, other molecules like receptor 
protein tyrosine phosphatase alpha (RPTPα), myocyte 
enhancer factor 2D (MEF2D), and runt-related transcription 
factor 2 (RUNX2) are post-transcriptional target molecules 
of miR-218, which are known to induce cancer metastasis 
like MACC1 [1, 50–52]. Rescue experiments with MACC1 
overexpression or knock-down of MACC1 and miR-218 
clearly revealed that MACC1 as a novel target of miR-218 
is at least in part responsible for the significant reduction 
of migration, invasion and colony formation by miR-218 
in CRC and gastric cancer cell lines [1, 15, 17]. EMT 
plays a major role in solid cancer tumor progression, 
which is triggered due to transcriptional preprograming 
[53]. MACC1 is known to induce c-MET as receptor 
tyrosine kinase involved in EMT and key transcriptional 
regulators like TWST1/2 [1, 54]. MACC1 is also a post-
transcriptional target of another miR, namely miR-338-3p, 
which targets the important EMT initiating transcription 
factor ZEB2 [26]. Like miR-338-3p, miR-218 is also 
a key EMT regulator, which targets for example ZEB2 
and the mesenchymal marker N-cadherin [28]. In tumor 
tissues, downregulation of the MACC1 post-transcriptional 
regulators, miR-218 and miR-338-3p, could be reasons for 
the MACC1 overexpression and its mediated EMT, cancer 
metastasis formation and drug resistance [28, 54, 55]. 
Figure 8: MACC1 possess alternative polyadenylation (APA) sites. (A) Schematic presentation of MACC1-3ʹ-UTR with miR-218 
seed sequence and the different preferential APA sites. (b) Gel electrophoresis of PCR products obtained from 3ʹ-RACE PCR.
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5-Aza is used for treatment of different types of 
leukemia and leads to global demethylation and activation 
of previously silenced gene promoters. Here, treatment 
of the CRC cell lines with 5-Aza showed an induction of 
miR-218 and SLIT2 expression. The luciferase activity of 
MACC1-3ʹ-UTR, MACC1 mRNA and protein expression 
were reduced in 5-Aza treated samples compared to 
DMSO controls. These results suggest that an epigenetic 
inhibition of miR-218 by hypermethylation of the SLIT2 
and SLIT3 promoter could be one of the reasons for 
MACC1 upregulation and its mediated poor survival 
of CRC patients and other cancer entities. Further, we 
haven’t observed any significant difference in miR-218 
expression between metachronous metastasis positive and 
negative specimens. This suggests that downregulation 
of miR-218 and MACC1 upregulation are early events 
during cancer development even before metastasis. In 
previous studies, the MACC1 expression was not tumor-
stage dependent which supports our findings [1, 2, 56]. 
In general, our findings strongly support the existing 
literature that miR-218 is a tumor suppressor gene and 
MACC1 is an oncogene [1, 57–62]. 
The 3ʹ-end of eukaryotic mRNAs possess a long 
stretch of untemplated adenosines termed as poly(A) 
tail, which plays a major role in processing of 3ʹ-ends 
and stability of mRNAs [63, 64]. Recent advances in 
RNA sequence and transcriptome sequencing methods 
revealed that most of the human genes contain more 
than one poly(A) site [38]. The preferential poly(A) 
sites determines the stability, cellular localization and 
translational efficiency of genes, since the 3ʹ-UTR 
serves as a docking site for regulatory miRNAs and RNA 
binding proteins [65, 66]. Lin et al. recently reported that 
a large fraction of mRNAs (around 30%) possess APA 
sites in 3ʹ-UTRs based on the cell type [36]. Secondly, a 
comparison of APA sites between the cultured mammary 
epithelial cell line MCF10A and the breast cancer cell 
lines MCF7 and MDA-MB-231 revealed that cancer 
cells showed in general shorter 3ʹ-UTRs [35]. This could 
mean that these cells harbor less miRNA binding sites, 
which could alter the post-transcriptional regulation of 
cancer-relevant genes. Similarly, MACC1 showed four 
APA sites in SW620 cells and among them the 5.7 kb 
3ʹ-UTR is the most prominent one. Since, it is known 
that MACC1 is upregulated in different cancer entities. 
One could speculate that in general this APA mechanism 
might also add regulatory complexity of this gene in 
tumors. 
In conclusion, all these findings highlight the pivotal 
role of miR-218 in various aspects of MACC1 expression 
regulation and MACC1-mediated CRC progression. 
Translated into clinical practice, the determination of miR-
218 and MACC1 expression in tumors could be used for 
better therapeutic designs. Induced MACC1 expression 
positively and miR-218 expression negatively mitigate 
the cancer stem cell functions, which are responsible for 
the tumor formation, growth and metastasis and resistance 
to chemotherapy [1, 3, 67]. Including our previous studies 
on MACC1 and other MACC1 and miR-218 published 
studies demonstrated that high MACC1 and low miR-
218 expressing cancer cells are resistant to chemotherapy 
[20, 55, 68, 69]. These accumulated evidences strongly 
suggest for a miR-218 replacement therapeutic approach 
for MACC1 high expressing CRC patients, which might 
resensitize patients for chemotherapy and increases the 
patient survival.
MAtErIALs AND MEtHODs 
Cell lines, cultures and drugs
Human CRC cell lines (RKO, HCT15, Colo320DM, 
HCT116, SW480, SW620, HT-29, Caco-2, WiDr and 
DLD-1) were purchased from American Type Culture 
Collection (ATCC; Manassas, VA) and Colo206f from 
German Collection of Microorganisms and Cell culture 
(DSMZ Leibniz Institute; Braunschweig, Germany). The 
gastric cancer cell line MKN-45 was kindly provided by 
the Experimental Pharmacology & Oncology Berlin-Buch 
GmbH (EPO; Berlin, Germany). Cells were grown at 
37°C with RPMI (Colo320DM, Colo206f, WiDr, SW480, 
HCT15) and DMEM (rest of the cells used for this study) 
media supplemented with 10% fetal calf serum (FCS). 
Original stock solutions of 5-aza-2ʹ-deoxycytidine (5-aza-
dC (#A2385), Sigma Chemical Co., St. Louis, MD) was 
stored at a concentration of 10 mM at –20°C and freshly 
dissolved in culture medium before use. 
miR, anti-miR and si-MACC1
mirVana® miRNA mimic miR-218-5p (ID: 
MC10328), mirVana® miRNA inhibitor anti-miR-218-5p 
(ID: MH10328), mirVana™ Negative Control (#4464058), 
Predesigned Silencer® Select si MACC1 (ID:s51181) and 
Silencer® Select siRNA negative control (#4390843) were 
purchased from Ambion, USA.
Patients and samples
Fresh snap-frozen surgical specimens of tumor 
tissues and representative corresponding normal specimens 
from 59 CRC patients were collected with informed 
written consent (approved by Charité Ethics Committee, 
Charité-Universitätsmedizin, Berlin), preserved and 
processed as explained in our previous publications 
[1, 25]. The main patients’ characteristics are reported in 
Supplementary Table S1. None of the patients received 
pre-operatory chemo/radiation therapy and none of the 
researchers conducting gene expression and statistical 
analyses had access to disclosed clinical-pathological data. 
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Construction of 3ʹ-UTR-luciferase plasmids and 
reporter assays
The 6016 bp length 3ʹ-UTR of MACC1 was amplified 
using cDNA from SW480 cells and cloned into the SacI 
and XhoI sites of the pmirGLO dual luciferase miRNA 
target expression vector (#E1330, Promega, USA). With 
specific MACC1-3ʹ-UTR sequencing primers, we checked 
for the orientation and accuracy of the 3ʹ-UTR sequence. 
Specific miR-218 seed sequence were mutated using site 
directed mutagenesis kit (#210518, QuickChange lightning 
site directed mutagenesis kit, Agilent technologies, USA). 
Primers used for cloning, mutation and sequencing of the 
3ʹ-UTR are presented in Supplementary Tables S2, S3 
and S4, respectively. For reporter assays, cells were co-
transfected using Lipofectamine 2000 (Invitrogen) with 
0.5 μg of dual luciferase construct along with 50 nM of 
control-miR or miRs/anti-miRs. Reporter assays were 
performed as described in the company protocol of Dual-
luciferase assay-system (Promega). Briefly, after 48 h of 
transfection, cells were lysed using passive lysis buffer 
and readings were taken for luciferase and then renilla 
for normalization. Percentage of luciferase activity was 
calculated as explained before [70].
DNA/rNA/Protein isolation and cDNA synthesis 
from cells and fresh snap-frozen CRC specimens
For isolation of DNA and RNA from frozen tissues, 
cryosections were performed and every fifth section was 
stained with hematoxylin. Tumor cell areas were evaluated 
and marked by a pathologist. Tumor cells were removed 
from the unstained slides and DNA was extracted by 
using ChargeSwitch® gDNA Micro Tissue Kit (#CS11203, 
Thermo Fisher), according to the manufacturer’s 
instructions. Similarly, RNA was extracted from tissues and 
cancer cells by using TRIzol reagent (Invitrogen). From the 
cancer cells, DNA was isolated using QIAamp DNA Mini 
Kit (#51304, Qiagen), according to the manufacturer’s 
instructions. DNA and RNA quality and concentration 
were measured using the Nano drop (Thermo Scientific). 
1 μg of total RNA was used to synthesize cDNA using 
miScript II RT Kit (Qiagen). Expression of mature miR-
218 (MS00006769, Qiagen) and U6-snRNA (RNUB6) 
(MS00033740, Qiagen) were determined by the miScript 
SYBR Green PCR Kit (Qiagen), and normalized using the 
2-ΔΔCt method relative to RNU6B. SLIT2 (QT00007784, 
Qiagen), MACC1 and RPII expression were measured 
as described above. SLIT2 and MACC1 expression were 
normalized to RPII expression. Primers are provided in 
Supplementary Table S5.
For protein extraction, cells were washed with PBS 
and lysed with RIPA buffer (50 mM TrisHCl [pH 7.5], 
150 mM NaCl, 1% Nonidet P-40, supplemented with 
complete protease inhibitor tablets; Roche Diagnostics) 
for 30 min on ice. Protein estimation and Western blot 
analysis were performed as described by Juneja et al. using 
specific antibodies for MACC1 (#Sigma-HPA020103) or 
β-actin (#SIGMA-A1978) [25]. 
Cell viability, migration, invasion and colony 
formation assay
Cells were seeded in 6-well plates and transfected 
with 50 nM control, miR-218 or anti-218 (Thermo 
Fisher Scientific) using Lipofectamine® RNAiMAX 
Reagent (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Cells were seeded for cell 
viability, migration, invasion and colony formation assay 
48 h after transfection.
For cell viability assay, 3.5 × 103 cells were seeded 
into 96-well plates. Quantification of cell viability was 
achieved using MTT (final concentration 0.5 mg/ml, 
Sigma) colorimetric assay. The absorption values at 560 
nm measured with the Infinite M200 Pro Reader (Tecan) 
were normalized to day 0 values and represented as fold-
changes of the corresponding control. The assay was 
repeated at least two independent times each in triplicates. 
Migration assay was performed using transwells 
(Costar) with 8 µm pores. 3 × 105 cells were seeded per 
well and quantified 16 h after seeding using CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega) according 
to the manufacturer’s instructions. For invasion assay 
transwells were coated with Matrigel (final concentration 
10 µg/100 µl, Corning) overnight at RT and performed 
the same way as described for migration assay. These 
assays were performed three independent times, each in 
triplicates. 
Soft agar colony formation assay was used 
to analyze the effects of the miRNA on anchorage-
independent cell proliferation. The bottom layer contained 
0.4% w/v agarose in DMEM or RPMI 1640 medium 
including 10% FCS and was added into 6 cm cell culture 
dish with grids (2 µm2, VWR). The top layer contained 
8 × 103 cells, 0.2 % w/v agarose in DMEM or RPMI 1640 
medium including 10% FCS and was added onto the 
solidified bottom layer. Cells were seeded as single cells 
into the soft agar and incubated in a humidified incubator 
at 37°C and 5% CO
2 
for 14 days. Colonies were visualized 
by 10× magnification in the Zeiss AXIO microscope 
(Zeiss). Colonies of more than 4 cells were counted and 
represented as normalized to the control group. The assay 
was repeated three independent times.
5-Aza-2ʹ-Deoxycytidine (5-aza-dC) treatment 
of cells, bisulfite conversion of DNA and 
methylation analysis
5ʹ-aza-dC (5-Aza) treatment, bisulfite conversion 
and methylation analyses (PCR was performed using 
HotStarTaq Plus DNA Polymerase (#203605, Qiagen), 
were performed as described previously [70, 71]. 
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MACC1, SLIT2 and miR-218 expression was quantified 
in comparison to DMSO-treated samples. CpG islands 
upstream of the TSS (Transcription start site) or pri-miR 
start site were determined with the CpG island searcher 
(http://www.uscnorris.com/cpgislands2/cpg.aspx), and 
PCR primers were designed using the Methprimer software 
(http://www.urogene.org/methprimer) approximately 
1000 bp upstream to the SLIT2, SLIT3 and miR-218 TSS. 
Primer sequences are provided in Supplementary Table S6. 
3ʹ-Race experiment
Total RNA was isolated using the Universal 
RNA Purification Kit (Roboklon) according to the 
manufacturerʼs instructions including the DNase I digest 
step. 1 µg of RNA isolated from SW620 cells was mixed 
with 5 µM oligo-dT primer and 500 µM dNTPs and 
incubated at 65°C for 5 min. After cooling down on ice for 
1 min a reaction mix for reverse transcription was prepared 
using 1 × RT buffer, 5 µM DTT, 40 U RiboBlock, 200 U 
SuperScriptIII (Thermo Scientific) and incubated at 50°C 
for 60 min and afterwards at 70°C for 15 min. Ampli Taq 
Gold (Thermo Scientific) was used for cDNA amplification 
according to the manufacturerʼs instructions. The PCR 
product was run on an agarose gel to visualize the different 
polyadenylated versions of the MACC1-3ʹ-UTR. Primer 
sequences are provided in Supplementary Table S7.
statistical analysis
All statistical analyses were performed with IBM® 
SPSS® Statistics 21 or GraphPad Prism version 5 (La 
Jolla). The comparison of two different groups was 
done by Student’s t-test. Comparison of three or more 
different treated groups was performed by one-way 
analysis of variance (ANOVA) and Bonferroni post hoc 
multiple comparison test. The non-parametric Spearmen 
correlation test was used for correlation analysis of 
MACC1 mRNA and miR-218 expression in CRC cell 
lines. Linear regression model was used to analyse the 
correlation between miR-218 and its host gene expression, 
SLIT2. MACC1 mRNA and miR-218 expression levels in 
tumor and normal specimen were examined using box 
and Whisker plots. Significant differences between two 
different groups were determined by Mann-Whitney 
U-test. All significance tests were two sided, and P-values 
less than 0.05 were defined as statistically significant.
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